Company: AEMD
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001683168-25-006049
Chunk: 12

Company: AETHLON MEDICAL INC
Filing Date: 2025-08-13
Form: 10-Q
Item: Item 1
Chunk 12
---
 Update No. 2024-02, Codification Improvements—Amendments
to Remove References to the Concepts Statements (“ASU 2024-02”). ASU 2024-02 eliminates various references to the FASB’s
Concepts Statements from the FASB Accounting Standards Codification in order to clarify that the Codification represents the authoritative
source of generally accepted accounting principles (GAAP) in the United States. The amendments do not alter existing accounting requirements.
The guidance is effective for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2024, and
early adoption is permitted. This ASU is not expected to have a material impact on the Company’s consolidated financial statements
or disclosures. 

     11 

5. EQUITY TRANSACTIONS IN THE THREE MONTHS ENDED JUNE 30, 2025

Reverse
Stock Split

Effective
as of the close of business on June 6, 2025 with an effective trading date of June 9, 2025,
we effected a 1-for-8 reverse stock split of our then outstanding shares of common stock. Accordingly, each 8 shares of outstanding
common stock then held by our stockholders were combined into one share of common stock. Any fractional shares resulting from the reverse
split were rounded up to the next whole share. Authorized common stock remained at 60,000,000 shares following the stock split.
The accompanying consolidated financial statements and accompanying notes have been retroactively revised to reflect such reverse stock
split as if it had occurred on April 1, 2024. All shares and per share amounts have been revised accordingly.

 Restricted Stock Unit Grants

In
April 2025, the Compensation Committee of the Board, or Compensation Committee, approved, pursuant to the terms of the Company’s
Amended and Restated Non-Employee Director Compensation Policy, or the Director Compensation Policy, the grant of the annual RSUs under
the Director Compensation Policy to each of the three non-employee directors of the Company then serving on the Board of Directors of
the Company, or Board. The Director Compensation Policy provides for a grant of stock options or $50,000 worth of RSUs at the beginning
of each fiscal year for current non-employee directors then serving on the Board, and for a grant of stock options or $75,000 worth of
RSUs for a newly elected non-employee director, with each